EpiCast Report: Rheumatoid Arthritis Market 2017 - Epidemiology Forecast to 2025 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025" drug pipelines to their offering.

In the 8MM, Epidemiologists forecast that the diagnosed incident cases of RA will increase from 195,592 cases in 2015 to 216,467 cases in 2025, at an Annual Growth Rate (AGR) of 1.07%. The US will have the highest number of diagnosed incident cases of RA among the 8MM throughout the forecast period, while Spain will have the lowest.

In the 8MM, Epidemiologists forecast that the diagnosed prevalent cases of RA will increase from 4,354,194 cases in 2015 to 4,931,572 cases in 2025, at an AGR of 1.33%. The US will have the highest number of diagnosed prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

In the 8MM, Epidemiologists forecast that the total prevalent cases of RA will increase from 6,137,523 cases in 2015 to 6,971,304 cases in 2025, at an AGR of 1.36%. The US will have the highest number of total prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

Epidemiologists utilized data from county-specific studies published in peer-reviewed journals as well as data obtained from primary research. In order to ensure comparability of the incidence and prevalence across markets, Epidemiologists used sources that provided the diagnosed incidence and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria for the classification of RA.

Scope

- The Rheumatoid Arthritis (RA) EpiCast Report provides an overview of the risk factors and global trends of RA in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, and total prevalent cases of RA segmented by age and sex in these eight markets. The diagnosed prevalent cases of RA are further segmented by severity in the 8 MM for the forecast period.

- The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/skn4z4/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Musculoskeletal Disorders Drugs, Musculoskeletal Disorders Drugs